RhumbLine Advisers’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-91,545
| Closed | -$821K | – | 2912 |
|
|
2016
Q3 | $821K | Sell |
91,545
-5,550
| -6% | -$39.5K | ﹤0.01% | 1929 |
|
|
2016
Q2 | $521K | Buy |
97,095
+15,246
| +19% | +$78.2K | ﹤0.01% | 2170 |
|
|
2016
Q1 | $377K | Sell |
81,849
-20
| -0% | -$80 | ﹤0.01% | 2404 |
|
|
2015
Q4 | $426K | Buy |
81,869
+7,487
| +10% | +$43.4K | ﹤0.01% | 2344 |
|
|
2015
Q3 | $450K | Buy |
74,382
+2,594
| +4% | +$31.8K | ﹤0.01% | 2303 |
|
|
2015
Q2 | $1.13M | Buy |
71,788
+11,930
| +20% | +$145K | ﹤0.01% | 1789 |
|
|
2015
Q1 | $651K | Buy |
59,858
+8,775
| +17% | +$89.6K | ﹤0.01% | 2132 |
|
|
2014
Q4 | $537K | Sell |
51,083
-1,875
| -4% | -$18.3K | ﹤0.01% | 2233 |
|
|
2014
Q3 | $508K | Sell |
52,958
-1,500
| -3% | -$15.3K | ﹤0.01% | 2211 |
|
|
2014
Q2 | $629K | Buy |
54,458
+2,646
| +5% | +$24.1K | ﹤0.01% | 2127 |
|
|
2014
Q1 | $518K | Sell |
51,812
-2,600
| -5% | -$37.5K | ﹤0.01% | 2206 |
|
|
2013
Q4 | $708K | Buy |
54,412
+1,430
| +3% | +$19.7K | ﹤0.01% | 2037 |
|
|
2013
Q3 | $792K | Buy |
52,982
+1,461
| +3% | +$17.5K | ﹤0.01% | 1933 |
|
|
2013
Q2 | $482K | Buy |
+51,521
| New | +$349K | ﹤0.01% | 2285 |
|
RhumbLine Advisers's RPTP Position: Q4 2016 in Review
RhumbLine Advisers sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q4 2016, closing a stake of 91,545 shares — an estimated $821K sold.
RhumbLine Advisers first reported a position in RPTP in Q2 2013 and held it in 14 quarters. The position peaked at $1.13M in Q2 2015. 0 funds tracked by Wall St. Rank hold RPTP as of Q4 2016.
- RhumbLine Advisers reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q4 2016 after selling out during the quarter.
- RhumbLine Advisers sold 91,545 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q4 2016, an estimated $821K.
- RhumbLine Advisers first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q2 2013 and held it in 14 quarters.
- RhumbLine Advisers's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $1.13M in Q2 2015.
- 0 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q4 2016.
Based on RhumbLine Advisers's 13F filing for Q4 2016, filed 27 Jan 2017.